Axon Enterprise, Inc $AXON Shares Acquired by Bessemer Group Inc.

Bessemer Group Inc. raised its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 13.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 225,097 shares of the biotechnology company’s stock after acquiring an additional 26,977 shares during the period. Bessemer Group Inc.’s holdings in Axon Enterprise were worth $127,840,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Evergreen Capital Management LLC lifted its stake in shares of Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the period. NorthCrest Asset Manangement LLC lifted its stake in shares of Axon Enterprise by 5.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 16 shares during the period. WPG Advisers LLC lifted its stake in shares of Axon Enterprise by 9.8% in the 3rd quarter. WPG Advisers LLC now owns 190 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 17 shares during the period. Monte Financial Group LLC lifted its stake in shares of Axon Enterprise by 5.5% in the 3rd quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 17 shares during the period. Finally, Wealth Alliance LLC lifted its stake in shares of Axon Enterprise by 3.2% in the 3rd quarter. Wealth Alliance LLC now owns 583 shares of the biotechnology company’s stock valued at $419,000 after purchasing an additional 18 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $391.88 on Friday. The firm has a market cap of $31.59 billion, a PE ratio of 157.38, a PEG ratio of 9.13 and a beta of 1.44. The firm has a fifty day moving average of $432.22 and a 200 day moving average of $515.47. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping the consensus estimate of $1.60 by $0.01. The company had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm’s revenue was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.47 EPS. As a group, research analysts predict that Axon Enterprise, Inc will post 1.41 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Erika Nardini sold 198 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total value of $100,302.84. Following the completion of the sale, the director owned 1,946 shares of the company’s stock, valued at approximately $985,804.68. The trade was a 9.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Jennifer H. Mak sold 1,500 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $573.45, for a total transaction of $860,175.00. Following the completion of the sale, the chief accounting officer directly owned 12,240 shares of the company’s stock, valued at approximately $7,019,028. The trade was a 10.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 13,855 shares of company stock worth $7,109,828 in the last 90 days. 4.40% of the stock is owned by insiders.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon’s Q1 results showed strong growth, with revenue up 34% year over year to $807 million and adjusted EBITDA of $202 million, suggesting the business is still expanding at a healthy pace. Axon shares rise as investors continue to digest strong Q1 results and recent large-agency contract momentum
• Positive Sentiment: Software and AI adoption appears to be gaining traction, with AI Era Plan-related product revenue rising more than 700% year over year, which supports the company’s higher-margin growth story. Axon shares rise as investors continue to digest strong Q1 results and recent large-agency contract momentum
• Positive Sentiment: New contract momentum is also encouraging, including a 10-year, $153 million city contract for upgraded body-worn cameras and TASER devices, reinforcing visibility into future revenue. Axon shares rise as investors continue to digest strong Q1 results and recent large-agency contract momentum
• Positive Sentiment: Brokerage sentiment remains constructive, with Axon receiving an average “Moderate Buy” rating and several firms reiterating overweight/outperform calls, which may be supporting the shares. Axon Enterprise, Inc (NASDAQ:AXON) Receives Average Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Axon is drawing attention as a trending stock, but that interest is more a sign of heightened investor focus than a clear fundamental catalyst. Axon Enterprise’s (NASDAQ:AXON) Problems Go Beyond Poor Profit
• Negative Sentiment: Some recent commentary has highlighted valuation and profitability concerns, reminding investors that the stock may face pressure if expectations cool after the post-earnings bounce. Axon Enterprise’s (NASDAQ:AXON) Problems Go Beyond Poor Profit

Wall Street Analyst Weigh In

Several research firms recently issued reports on AXON. Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Citizens Jmp decreased their target price on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating for the company in a research note on Thursday, May 7th. Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Needham & Company LLC decreased their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Finally, Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a research note on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $712.75.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.